Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study

Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study

Background: Oncotype DX (ODX) is a validated assay for the prediction of risk of recurrence and benefit of chemotherapy (CT) in both node negative (N0) and 1–3 positive nodes (N1), hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) early breast cancer (eBC). D...

Full description

Bibliographic Details
Main Authors: Leandro Jonata Carvalho Oliveira, Thais Baccili Cury Megid, Daniela Dornelles Rosa, Carlos Alberto da Silva Magliano, Daniele Xavier Assad, Daniel Fontes Argolo, Solange Moraes Sanches, Laura Testa, José Bines, Rafael Kaliks, Maira Caleffi, Debora de Melo Gagliato, Marina Sahade, Romualdo Barroso-Sousa, Tatiana Strava Corrêa, Andrea Kazumi Shimada, Daniel Negrini Batista, Daniel Musse Gomes, Marcelle Goldner Cesca, Débora Gaudêncio, Larissa Matos Almeida Moura, Julio Antonio Pereira de Araújo, Artur Katz, Max Senna Mano
Format: Article
Language:English
Published: SAGE Publishing 2022-12-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359221141760

Internet

https://doi.org/10.1177/17588359221141760

Similar Items